Fri, Dec 19, 2014, 12:52 PM EST - U.S. Markets close in 3 hrs 8 mins


% | $
Quotes you view appear here for quick access.

Obagi Medical Products, Inc. (OMPI) Message Board

  • nycwest nycwest Mar 20, 2013 9:20 AM Flag



    March 20, 2013
    New York, New York

    Tripp Levy PLLC, a leading national securities and shareholder rights law firm, announces that it is investigating the acquisition of Obagi Medical Products, Inc (OMPI). Obagi announced that it entered into a definitive merger agreement with Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) (“Valeant”) under which Valeant will acquire all of the outstanding common stock of Obagi for $19.75 per share in cash.

    The investigation concerns whether the board of directors of Obagi breached its fiduciary duties by not engaging in a full and fair auction of the company to allow shareholders to obtain the highest price possible for their shares, while, at the same time, negotiating personal pay packages and benefits for themselves that will not be shared with shareholders.

    If you are a shareholder of Obagi and would like additional information concerning this transaction at no cost or expense please contact us toll free at 1-877-772-3975 or email at contact @ tripplevy

    This topic is deleted.
    SortNewest  |  Oldest  |  Most Replied Expand all replies

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.